| Name | Ensitrelvir fumarate |
|---|---|
| Synonyms |
Ensitrelvir fumate
S-217622 Ensitrelvir fumate(S-217622) (E) - 6 - ((6-chloro-2-methyl-2h-indazole-5-yl) imino) - 3 - ((1-methyl-1h-1,2,4-triazol-3-yl) methyl) - 1 - (2,4,5-trifluorobenzyl) - 1,3,5-triazinane-2,4-dione fumate S-217622-002-C4H4O4 S-217622 fumate Ensitrelvir Fumic Acid 1,3,5-Triazine-2,4(1H,3H)-dione, 6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]dihydro-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-, (6E)-, (2E)-2-butenedioate (1:1) Ensitrelvir Fumate (S-217622 Fumate) (E)-6-((6-Chloro-2-methyl-2H-indazol-5-yl)imino)-3-((1-methyl-1H-1,2,4-triazol-3-yl)methyl)-1-(2,4,5-trifluorobenzyl)-1,3,5-triazinane-2,4-dione fumate RMA-43 |
| Description | Ensitrelvir (S-217622) fumarate is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM)[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | In a cytopathic effect (cpe)-inhibition assay of SARS-CoV-2 infected VeroE6/TMPRSS2 cells, Ensitrelvir fumarate shows the EC50 values are approximately 0.4 μM for both wild-type virus and Alpha, Beta, Gamma and Delta variants. EC50 values for SARS-CoV and MERS-CoV were 0.21 and 1.4 μM respectively[1]. |
| In Vivo | Ensitrelvir fumarate dose-dependently inhibits intrapulmonary replication of SARS-CoV-2 in mice[2]. |
| References |
| Molecular Formula | C26H21ClF3N9O6 |
|---|---|
| Molecular Weight | 647.95 |